SecBot SecBot
8-K ·Filed Feb 24, 2026

TMDX

TransMedics Group, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001193125-26-066953
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The core business growth is very strong with 32-37% revenue growth and expanding full-year gross margins. The significant tax benefit is non-recurring, so future quarters will not see this level of net income. However, the robust 2026 guidance suggests continued strong top-line growth, making this a bullish signal for the stock despite the accounting anomaly in net income.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$131.85
T+0 close · Feb 24, 2026 · via day close
Latest settled
−48.43%
T+60 · $68.00
Vs SPY
−55.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $131.85entry
  2. T+1 · 9mo ago +2.06%α +2.61% · $134.57
  3. T+5 · 9mo ago +11.99%α +13.09% · $147.66
  4. T+20 · 8mo ago −20.27%α −15.03% · $105.13
  5. T+60 · 6mo ago −48.43%α −55.38% · $68.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TransMedics reported strong fourth quarter and full year 2025 financial results, with revenue up 32% and 37% respectively, driven by increased utilization of its Organ Care System. Net income surged to $105.4 million in Q4 and $190.3 million for the full year, significantly boosted by a one-time $83.8 million tax benefit from the release of a valuation allowance. The company also provided 2026 revenue guidance of $727-$757 million, representing 20-25% growth.

Key Financial Metrics

Revenue
$605.5M
+37.0% YoY
EPS
$4.87
Guidance
$727M-$757M
raised
Gross Margin
60%

Key Facts

  • Q4 2025 revenue was $160.8 million, up 32% YoY from $121.6 million in Q4 2024
  • Full year 2025 revenue was $605.5 million, up 37% YoY from $441.5 million in 2024
  • Q4 net income was $105.4 million ($2.62 diluted EPS), including an $83.8 million tax benefit
  • Full year net income was $190.3 million ($4.87 diluted EPS), including an $82.8 million tax benefit
  • 2026 revenue guidance is $727-$757 million, representing 20-25% growth over 2025
  • Gross margin was 58% in Q4 2025 (down from 59% in Q4 2024) and 60% for full year 2025 (up from 59% in 2024)

Financial Impact

Revenue growth of 32-37% and 2026 guidance of 20-25% growth indicate strong momentum. The $83.8 million tax benefit significantly inflated Q4 net income, which would have otherwise been $21.6 million.

revenueepsnet incomemarginscash flow

Segment Breakdown

SegmentRevenueGrowth
Net product revenue$372.4M+36.0%
Service revenue$233.1M+39.0%

Risk Factors

  • The substantial net income in Q4 and full year 2025 was heavily influenced by a one-time $83.8 million tax benefit, which is not sustainable
  • Gross margin declined slightly in Q4 2025 to 58% from 59% in Q4 2024 due to higher clinical service and freight costs
  • Forward-looking statements in the filing highlight numerous risks including regulatory, reimbursement, and execution risks for new programs

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-066953
Document: tmdx-20260224.htm0001193125-26-066953
Document: 0001193125-26-066953-index-headers.html0001193125-26-066953
Document: 0001193125-26-066953-index.html0001193125-26-066953
Document: 0001193125-26-066953.txt0001193125-26-066953
CONTEXT: Previous Earnings (2026-02-24)0001193125-26-066953

Track record

9 reports on TMDX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +22.27% at T+60 after the Jun 11, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago 144 Neutral 2/10 Entry $90.95 Now $92.21 +1.39% settles Nov 17
  2. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $88.24 to $91.38 Now $92.21 +4.50% ▲ +3.56% +0.96% vs SPY
  3. Nov 5, 202611d ago Press Release Bullish 6/10 No price data
  4. Jun 12, 202622w ago Institutional Cluster Bullish 6/10 Entry $72.91 to $78.79 Now $92.21 +26.47% ▲ +8.06% +7.39% vs SPY
  5. Jun 11, 202622w ago Institutional Cluster Bullish 5/10 Entry $73.59 to $73.22 Now $92.21 +25.30% ▼ −0.50% −0.94% vs SPY
  6. Apr 10, 202631w ago DEFA14A Neutral 3/10 Entry $114.00 to $115.87 Now $92.21 −19.11% ▲ +1.64% −2.86% vs SPY
  7. Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $147.00 to $134.77 Now $92.21 −37.27% ▼ −8.32% −7.11% vs SPY
  8. Feb 27, 202637w ago 8-K Neutral 4/10 Entry $145.26 to $129.61 Now $92.21 −36.52% ▼ −10.77% −8.79% vs SPY
  9. Feb 24, 202637w ago 8-K Bullish 8/10 Viewing Entry $131.85 to $147.66 Now $92.21 −30.06% ▲ +11.99% +13.09% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 12m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 24, 2026